Other Names 
Bromantane has been used in Russia since the late 1980s without a prescription by sportsmen and soldiers. It is an adamantane derivative and was originally developed as an immuno-stimulant drug. Bromantane is simultaneously a stimulant and an anxiolytic. In 1996 it was listed in the IOC list of prohibited substances shortly after it was discovered being used by several athletes in that year’s Olympic Games.
Modes of Action
Bromantane stimulates the nervous system through dopaminergic action
Bromantane stimulates serotonin receptors by increasing 5-HT and 5-HIAA in the frontal cortex and subcortical regions of the brain
Bromantane reduces 5-HT and 5-HIAA in the cerebellum
Bromantane strengthens GABA-ergic mediation, reducing gene expression, supervising synthesis of GABA-transporters
Bromantane stimulates synthesis of cytochrome P-450
Increases both mental and physical work capacity
Increases learning and memory
Stimulant effect differs from traditional psychostimulants in that it is an agent of non-exhaustive action (no increase in oxygen consumption or body heat). 
Boosts immune system
Increases muscle mass and strength
Reduces overheating and helps protect against hyperthermia
Very few side-effects
No withdrawl symptoms or addictive potential
Helps liver with detoxification functions
Bromantane dosing appears to be sex-dependent. When taken orally, bromantane is quickly absorbed by the gastrointestinal tract into the bloodstream (42%). Bromantane is highly lipophilic. Females absorb bromantane significantly quicker than males and therefore in females bromantane a much shorter half-life in females as opposed to males. Time to achievement is 2.75 hours in females and 4 hours in males.
The effective dose for bromantane is 30mg/kg in the rat. At 30mg/kg, bromantane has a stimulant effect. At toxic doses (600mg/kg), bromantane has a sedating effect.
In animal studies, toxicity was reached only at very high levels of administration. Toxic effects begin around 600mg/kg in mice and the LD50 is much higher in one animal study performed in Russia of 8100mg/kg injected intraperitoneally.
1. CSID:3849628, http://www.chemspider.com/Chemical-Structure.3849628.html (accessed 21:30, Apr 22, 2013)
2. Schänzer, W. Recent Advances in Doping Analysis: Proceeding of the Mandred Donike 16th Cologne Workshop on Dope Analysis, 15th to 20th March 1998. Köln: Sport Und Buch Strauss, 1999. Print.
3. Thieme, Detlef, and Peter Hemmersbach. Doping in Sports: Biochemical Principles, Effects and Analysis. N.p.: Springer, 2009. Print.
6. Oliynyk, Sergiy, and Seikwan Oh. “The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance.” Biomolecules & Therapeutics (2012): 444-55. Print.